How to cite item

Distinct benefit from crizotinib in lung cancer patients carrying distinct ALK translocations: is fluorescent hybridization in situ testing still sufficient to guide clinical decisions?

   
@article{TCR11193,
	author = {Natalia V. Mitiushkina and Evgeny N. Imyanitov},
	title = {Distinct benefit from crizotinib in lung cancer patients carrying distinct ALK translocations: is fluorescent hybridization in situ testing still sufficient to guide clinical decisions?},
	journal = {Translational Cancer Research},
	volume = {5},
	number = {Suppl 7},
	year = {2016},
	keywords = {},
	abstract = {ALK rearrangements in lung cancer (LC) were discovered in the year 2007 upon the systematic search for novel LC-associated oncogenes (1,2). Fortunately, an experimental MET inhibitor, PF-2341066 (crizotinib), was by then known to have a concurrent ALK-inhibiting activity and its clinical profile was already under phase I evaluation (3-6). It was quickly revealed that the status of ALK, but not MET, is a primary determinant of tumor sensitivity to crizotinib (5), and a number of subsequent studies heralded a real breakthrough in the treatment of ALK-rearranged cancers (6-9).},
	issn = {2219-6803},	url = {https://tcr.amegroups.org/article/view/11193}
}